Exactech Names Michael Simpson Vice President of Regulatory and Clinical Affairs
Gainesville, FL, September 26, 2005 -- Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products including orthopaedic implants and biologic materials, announced today the appointment of Michael Simpson as vice president of regulatory and clinical affairs.
Gainesville, FL, September 26, 2005 -- Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products including orthopaedic implants and biologic materials, announced today the appointment of Michael Simpson as vice president of regulatory and clinical affairs.
Simpson will lead the development of corporate strategies and company policies to ensure quality certification and FDA compliance. He will spearhead compliance with domestic and international requirements such as 510(k) clearance, pre-market approval, product registration/licensing and International Standards Organization certification.
Exactech CEO Bill Petty said, “Mike brings strong leadership skills and demonstrated success in leading continuous improvement and organizational change. His experience with medical device regulatory submissions, including investigational device exemption and pre-market approvals, quality system development and management proficiency, will enhance Exactech’s aggressive product development initiatives.”
Simpson joins Exactech from SaluMedica, LLC in Atlanta, Ga., where he was director of quality and regulatory affairs. He holds a master’s degree in mechanical engineering with emphasis in bioengineering from the Georgia Institute of Technology.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States and in more than 25 countries in Europe, Asia, Australia and Latin America.
An investment profile on Exactech may be found at
http://www.hawkassociates.com/exactech/profile.htm.
Additional information about Exactech, Inc. can be found at http://www.exac.com. An online virtual investor relations kit containing Exactech press releases, SEC filings, current price quotes, stock charts and other useful information for investors can be found on the Hawk Associates website, http://www.hawkassociates.com. Investors may contact Chief Financial
Officer Jody Phillips at (352) 377-1140 or Julie Marshall or Frank Hawkins, Hawk Associates
Inc., at (305) 451-1888, e-mail: info@hawkassociates.com.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third-party manufacturers to produce components on a basis that is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.
